FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 316:1506-1510 June 11, 1987 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Patients with allergic rhinitis often have immediate symptoms after antigen challenge (the early-phase response), followed several hours later by a recurrence of symptoms (the late-phase response). Systemic glucocorticosteroids are known to inhibit the late-phase but not the early-phase response. We studied the effect of one week of pretreatment with topical (rather than systemic) glucocorticosteroids on the response to nasal challenge with antigen in a double-blind, randomized, placebo-controlled crossover study of 13 allergic patients who had previously had a dual response to nasal challenge. The patients were challenged with three 10-fold increments of allergen, producing an early response, and were then followed for 11 hours, encompassing the late response, before they were rechallenged with the lowest dose of allergen. We monitored their responses by means of symptom scores and measurements of the levels of histamine, tosyl-L-arginine methyl ester (TAME)-esterase activity, and kinins in nasal lavages. Topical glucocorticosteroids significantly reduced both the symptoms and the levels of histamine, TAME-esterase activity, and kinins in the early, late, and rechallenge allergic reactions. The fact that, in contrast to treatment with systemic glucocorticosteroids, prolonged pretreatment with topical glucocorticosteroids inhibited the early-phase response to antigen suggests that the route and duration of administration affect the mechanisms of action of the steroids. We conclude that inhibition of the early-phase as well as the late-phase response by topical glucocorticosteroids may provide an advantage over treatment with systemic glucocorticosteroids in patients with allergic rhinitis.

This article has been cited by other articles:

• Schramm, B., Ehlken, B., Smala, A., Quednau, K., Berger, K., Nowak, D. (2003). Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 21: 116-122 [Abstract] [Full Text]  
• Kaszuba, S. M., Baroody, F. M., deTineo, M., Haney, L., Blair, C., Naclerio, R. M. (2001). Superiority of an Intranasal Corticosteroid Compared With an Oral Antihistamine in the As-Needed Treatment of Seasonal Allergic Rhinitis. Arch Intern Med 161: 2581-2587 [Abstract] [Full Text]  
• Baroody, F. M., Cheng, C.-C., Moylan, B., deTineo, M., Haney, L., Reed, K. D., Cook, C. K., Westlund, R. E., Sengupta, E., Corey, J. P., Togias, A., Naclerio, R. M. (2001). Absence of Nasal Mucosal Atrophy With Fluticasone Aqueous Nasal Spray. Arch Otolaryngol Head Neck Surg 127: 193-199 [Abstract] [Full Text]  
• LINDEN, M., SVENSSON, C., ANDERSSON, E., ANDERSSON, M., GREIFF, L., PERSSON, C. G. A. (2000). Immediate Effect of Topical Budesonide on Allergen Challenge-induced Nasal Mucosal Fluid Levels of Granulocyte-Macrophage Colony-stimulating Factor and Interleukin-5. Am. J. Respir. Crit. Care Med. 162: 1705-1708 [Abstract] [Full Text]  
• Giembycz, M. A., Lindsay, M. A. (1999). Pharmacology of the Eosinophil. Pharmacol. Rev. 51: 213-340 [Abstract] [Full Text]  
• BAROODY, F. M., ROUADI, P., DRISCOLL, P. V., BOCHNER, B. S., NACLERIO, R. M. (1998). Intranasal Beclomethasone Reduces Allergen-induced Symptoms and Superficial Mucosal Eosinophilia without Affecting Submucosal Inflammation. Am. J. Respir. Crit. Care Med. 157: 899-906 [Abstract] [Full Text]  
• Committee on Drugs, (1997). Alternative Routes of Drug Administration---Advantages and Disadvantages (Subject Review). Pediatrics 100: 143-152 [Abstract] [Full Text]  
• Smith, D. L., deShazo, R. D. (1994). Allergy and Immunology. JAMA 271: 1653-1654 [Abstract]